Author

E. P. Henske

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

J. M. Asara· 2 shared A. J. Valvezan· 1 shared B. D. Manning· 1 shared C. Ye· 1 shared D. J. Kwiatkowski· 1 shared H. C. Lam· 1 shared H. Du· 1 shared H. Filippakis· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

J. M. Asara

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and rewires the microenvironment toward an immune-suppressive state

Y. Tang, D. J. Kwiatkowski, E. P. Henske

This study identifies a stem-like tumor cell state in TSC-associated tumors that drives resistance to mTOR inhibition and promotes an immune-suppressive microenvironment through midkine expression.

bioRxiv · Jun 1, 2022 · PreprintCancer Biology

Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells

J. Wang, H. Filippakis, T. Hougard, H. Du, C. Ye, H.-J. Liu, L. Zhang, K. Hindi, S. Bagwe, J. Nijmeh, J. M. Asara, W. Shi, S. Y. El-Chemaly, E. P. Henske, H. C. Lam

This study shows that IL-6 promotes PSAT1 expression and serine metabolism in TSC2-deficient cells, linking IL-6 to mTORC1 hyperactivity and potential therapeutic targets.

bioRxiv · May 17, 2021Pathology

IMPDH inhibitors for anti-tumor therapy in tuberous sclerosis complex

A. J. Valvezan, S. K. Miller, M. C. McNamara, M. E. Torrence, J. M. Asara, E. P. Henske, B. D. Manning

This paper evaluates IMPDH inhibitors for anti-tumor therapy in TSC, finding mizoribine more effective than mycophenolic acid in targeting mTORC1-driven tumors.

bioRxiv · Nov 11, 2019Cancer Biology